Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

References

• Maher TM Wells AU Laurent GJ Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir Journal 2007 30 5 835 839
   PubMed Web of Science ®Google Scholar
• Navaratnam V Fleming KM West J The rising incidence of idiopathic pulmonary fibrosis in the UK Thorax 2011 66 6 462 467 21525528
   PubMed Web of Science ®Google Scholar
• Gribbin J Hubbard RB Le JI Smith CJ West J Tata LJ Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK Thorax 2006 61 11 980 985 16844727
   PubMed Web of Science ®Google Scholar
• Raghu G Weycker D Edelsberg J Bradford WZ Oster G Incidence and prevalence of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2006 174 7 810 816 16809633
   PubMed Web of Science ®Google Scholar
• Navaratnam V Fogarty A Glendening R McKeever T Hubbard RB The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010 Chest Epub 9 24 2012
   Google Scholar
• Ley B Collard HR King TEJr Clinical course and prediction of survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 183 4 431 440 20935110
   PubMed Web of Science ®Google Scholar
• Datta A Scotton CJ Chambers RC Novel therapeutic approaches for pulmonary fibrosis Br J Pharmacol 2011 163 1 141 172 21265830
   PubMed Web of Science ®Google Scholar
• King TEJr Pardo A Selman M Idiopathic pulmonary fibrosis Lancet 2011 378 9807 1949 1961 21719092
   PubMed Web of Science ®Google Scholar
• Maher TM Pirfenidone in idiopathic pulmonary fibrosis Drugs Today (Barc) 2010 46 7 473 482 20683502
   PubMed Web of Science ®Google Scholar
• Roth GJ Heckel A Colbatzky F Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J Med Chem 2009 52 14 4466 4480 19522465
   PubMed Web of Science ®Google Scholar
• Richeldi L Costabel U Selman M Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 2011 365 12 1079 1087 21992121
   PubMed Web of Science ®Google Scholar
• Hilberg F Roth GJ Krssak M BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 2008 68 12 4774 4782 18559524
   PubMed Web of Science ®Google Scholar
• Santos ES Gomez JE Raez LE Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor Invest New Drugs 2012 30 3 1261 1269 21350804
   PubMed Web of Science ®Google Scholar
• Ellis PM Kaiser R Zhao Y Stopfer P Gyorffy S Hanna N Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients Clinical Cancer Res 2010 16 10 2881 2889 20460487
   PubMed Web of Science ®Google Scholar
• du Bois A Huober J Stopfer P A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies Ann Oncol 2010 21 2 370 375 19889612
   PubMed Web of Science ®Google Scholar
• Doebele RC Conkling P Traynor AM A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 2012 23 8 2094 2102 22345119
   PubMed Web of Science ®Google Scholar
• Kropff M Kienast J Bisping G An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma Anticancer Res 2009 29 10 4233 4238 19846979
   PubMed Web of Science ®Google Scholar
• Ledermann JA Hackshaw A Kaye S Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J Clin Oncol 2011 29 28 3798 3804 21859991
   PubMed Web of Science ®Google Scholar
• Chaudhary NI Roth GJ Hilberg F Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur Respir J 2007 29 5 976 985 17301095
   PubMed Web of Science ®Google Scholar
• Taeger J Moser C Hellerbrand C Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer Mol Cancer Ther 2011 10 11 2157 2167 21885862
   PubMed Web of Science ®Google Scholar
• Akhurst RJ Hata A Targeting the TGFbeta signalling pathway in disease Nat Rev Drug Discov 2012 11 10 790 811 23000686
   PubMed Web of Science ®Google Scholar
• Antoniades HN Bravo MA Avila RE Platelet-derived growth factor in idiopathic pulmonary fibrosis J Clin Invest 1990 86 4 1055 1064 2170444
   PubMed Web of Science ®Google Scholar
• Bonner JC Regulation of PDGF and its receptors in fibrotic diseases Cytokine and Growth Factor Reviews 2004 15 4 255 273 15207816
   PubMed Web of Science ®Google Scholar
• Battegay EJ Raines EW Colbert T Ross R TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression Journal of immunology 1995 154 11 6040 6047
   PubMed Web of Science ®Google Scholar
• Battegay EJ Raines EW Seifert RA Bowen-Pope DF Ross R TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop Cell 1990 63 3 515 524 2171777
   PubMed Web of Science ®Google Scholar
• Kolb M Margetts PJ Anthony DC Pitossi F Gauldie J Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis J Clin Invest 2001 107 12 1529 1536 11413160
   PubMed Web of Science ®Google Scholar
• Yoshida M Sakuma J Hayashi S A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene Proc Nat Academy of Sciences of the United States of America 1995 92 21 9570 9574
   Web of Science ®Google Scholar
• Rice AB Moomaw CR Morgan DL Bonner JC Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats Am Journal Pathol 1999 155 1 213 221 10393853
   PubMed Web of Science ®Google Scholar
• Abdollahi A Li M Ping G Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J Exp Med 2005 201 6 925 935 15781583
   PubMed Web of Science ®Google Scholar
• Martinet Y Rom WN Grotendorst GR Martin GR Crystal RG Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis N Engl J Med 1987 317 4 202 209 3600711
   PubMed Web of Science ®Google Scholar
• Homma S Nagaoka I Abe H Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung Am J Respir Crit Care Med 1995 152 6 Pt 1 2084 2089 8520779
   PubMed Web of Science ®Google Scholar
• Daniels CE Wilkes MC Edens M Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 2004 114 9 1308 1316 15520863
   PubMed Web of Science ®Google Scholar
• Daniels CE Lasky JA Limper AH Mieras K Gabor E Schroeder DR Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 2010 181 6 604 610 20007927
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G Hollinger MA Giri SN Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level Am Journal Physiol 1999 276 2 Pt 1 L311 L318 9950894
   PubMed Web of Science ®Google Scholar
• Henke C Fiegel V Peterson M Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury J Clin Invest 1991 88 4 1386 1395 1717512
   PubMed Web of Science ®Google Scholar
• Inoue Y King TEJr Barker E Daniloff E Newman LS Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis Am J Respir Crit Care Med 2002 166 5 765 773 12204879
   PubMed Web of Science ®Google Scholar
• Fan H Duan Y Zhou H Selection of peptide ligands binding to fibroblast growth factor receptor 1 IUBMB Life 2002 54 2 67 72 12440521
   PubMed Web of Science ®Google Scholar
• Calandrella N Risuleo G Scarsella G Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor J Exp Cin Cancer Res 2007 26 3 405 409
   Web of Science ®Google Scholar
• Yu ZH Wang DD Zhou ZY He SL Chen AA Wang J Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice Biol Pharm Bull 2012 35 5 731 736 22687409
   PubMed Web of Science ®Google Scholar
• Olsson AK Dimberg A Kreuger J Claesson-Welsh L VEGF receptor signalling – in control of vascular function Nat Rev Mol Cell Biol 2006 7 5 359 371 16633338
   PubMed Web of Science ®Google Scholar
• Farkas L Farkas D Ask K VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats J Clin Invest 2009 119 5 1298 1311 19381013
   PubMed Web of Science ®Google Scholar
• Renzoni EA Walsh DA Salmon M Interstitial vascularity in fibrosing alveolitis Am J Respir Crit Care Med 2003 167 3 438 443 12406847
   PubMed Web of Science ®Google Scholar
• Keane MP Arenberg DA Lynch JPIII The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis J Immunol 1997 159 3 1437 1443 9233641
   PubMed Web of Science ®Google Scholar
• Nissen LJ Cao R Hedlund EM Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis J Clin Invest 2007 117 10 2766 2777 17909625
   PubMed Web of Science ®Google Scholar
• Hamada N Kuwano K Yamada M Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice J Immunol 2005 175 2 1224 1231 16002726
   PubMed Web of Science ®Google Scholar
• Mross K Stefanic M Gmehling D Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors Clin Cancer Res 2010 16 1 311 319 20028771
   PubMed Web of Science ®Google Scholar
• Okamoto I Kaneda H Satoh T Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors Mol Cancer Ther 2010 9 10 2825 2833 20688946
   PubMed Web of Science ®Google Scholar
• Stopfer P Rathgen K Bischoff D Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers Xenobiotica 2011 41 4 297 311 21204634
   PubMed Web of Science ®Google Scholar
• Gori B Ricciardi S Fulvi A Intagliata S Del Signore E de Marinis F New antiangiogenics in non-small cell lung cancer treatment: vargatef (BIBF 1120) and beyond Ther Clin Risk Manag 2011 7 429 440 22241943
   PubMed Web of Science ®Google Scholar
• Raghu G Collard HR Anstrom KJ Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials Am J Respir Crit Care Med 2012 185 10 1044 1048 22505745
   PubMed Web of Science ®Google Scholar
• du Bois RM Nathan SD Richeldi L Schwarz MI Noble PW Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials Am J Respir Crit Care Med 2012 186 8 712 715 22798316
   PubMed Web of Science ®Google Scholar
• Wells AU Behr J Costabel U European IPFCG Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 2012 67 11 938 940 23047830
   PubMed Web of Science ®Google Scholar
• du Bois RM Weycker D Albera C Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 184 4 459 466 21616999
   PubMed Web of Science ®Google Scholar
• Taniguchi H Ebina M Kondoh Y Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 2010 35 4 821 829 19996196
   PubMed Web of Science ®Google Scholar
• Collard HR Idiopathic pulmonary fibrosis and pirfenidone Eur Respir J 2010 35 4 728 729 20356985
   PubMed Web of Science ®Google Scholar
• Richeldi L Brown KK Costabel U Efficacy of the tyrosine kinase inhibitor BIBF 1120 in patients with IPF: consistent pattern of primary endpoint results in sensitivity analyses of the TOMORROW trial Am J Respir Crit Care Med 2012 185 1 Meeting Abstracts A3633
   Google Scholar
• Brown KK Richeldi L Costabel U Treatment of IPF with the tyrosine kinase inhibitor BIBF 1120: patient-reported outcomes in the TOMORROW trial Am Journal of Respiratory and Critical Care Medicine 2012 185 1 Meeting Abstracts A3634
   Google Scholar
• Swigris JJ Brown KK Behr J The SF-36 and SGRQ: validity and first look at minimum important differences in IPF Respir Med 2010 104 2 296 304 19815403
   PubMed Web of Science ®Google Scholar
• Collard HR Moore BB Flaherty KR Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2007 176 7 636 643 17585107
   PubMed Web of Science ®Google Scholar
• Huie TJ Olson AL Cosgrove GP A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes Respirology 2010 15 6 909 917 20546190
   PubMed Web of Science ®Google Scholar
• Azuma A Nukiwa T Tsuboi E Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2005 171 9 1040 1047 15665326
   PubMed Web of Science ®Google Scholar
• Noble PW Albera C Bradford WZ Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 2011 377 9779 1760 1769 21571362
   PubMed Web of Science ®Google Scholar
• Bouche O Maindrault-Goebel F Ducreux M Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer Anticancer Res 2011 31 6 2271 2281 21737652
   PubMed Web of Science ®Google Scholar
• Reck M Kaiser R Eschbach C A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann Oncol 2011 22 6 1374 1381 21212157
   PubMed Web of Science ®Google Scholar